Regeneron Pharmaceuticals EBITDA vs. Earnings Per Share
| REGN Stock | USD 754.87 1.84 0.24% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 4 B | Current Value 4.2 B | Quarterly Volatility 2.5 B |
For Regeneron Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Regeneron Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Regeneron Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Regeneron Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Regeneron Pharmaceuticals over time as well as its relative position and ranking within its peers.
Regeneron |
Regeneron Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.46 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Regeneron Pharmaceuticals Earnings Per Share vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Regeneron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Regeneron Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Regeneron Pharmaceuticals is currently regarded as top stock in ebitda category among its peers. It also is currently regarded as top stock in earnings per share category among its peers . The ratio of EBITDA to Earnings Per Share for Regeneron Pharmaceuticals is about 100,027,187 . At this time, Regeneron Pharmaceuticals' EBITDA is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regeneron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Regeneron Pharmaceuticals' Earnings Breakdown by Geography
Regeneron Earnings Per Share vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Regeneron Pharmaceuticals |
| = | 4.05 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Regeneron Pharmaceuticals |
| = | 40.46 X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Regeneron Earnings Per Share Comparison
Regeneron Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Regeneron Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Regeneron Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Regeneron Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Regeneron Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Regeneron Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -80.9 M | -76.9 M | |
| Operating Income | 4 B | 4.2 B | |
| Net Income | 4 B | 4.2 B | |
| Income Before Tax | 4.2 B | 4.4 B | |
| Total Other Income Expense Net | 152.2 M | 159.8 M | |
| Income Tax Expense | 245.7 M | 169.5 M | |
| Net Income Applicable To Common Shares | 5 B | 5.2 B | |
| Net Income From Continuing Ops | 4 B | 2.2 B | |
| Non Operating Income Net Other | 206.2 M | 216.5 M | |
| Interest Income | 417.7 M | 438.6 M | |
| Net Interest Income | 345.6 M | 362.9 M | |
| Change To Netincome | 608.9 M | 639.3 M | |
| Net Income Per Share | 37.05 | 38.91 | |
| Income Quality | 1.16 | 0.63 | |
| Net Income Per E B T | 0.94 | 1.10 |
Regeneron Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Regeneron Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Regeneron Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Regeneron Pharmaceuticals' important profitability drivers and their relationship over time.
Use Regeneron Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Regeneron Pharmaceuticals Pair Trading
Regeneron Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Regeneron Pharmaceuticals position
In addition to having Regeneron Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Measuring and Control Equipment Thematic Idea Now
Measuring and Control Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Measuring and Control Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Measuring and Control Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
To fully project Regeneron Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Regeneron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Regeneron Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.